

ENDOLOGIX INC /DE/
Form 8-K
October 25, 2007

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT**
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 22, 2007
ENDOLOGIX, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-28440	68-0328265
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
11 Studebaker, Irvine, CA		92618
(Address of principal executive offices)		(Zip Code)
	Registrant's telephone number, including area code: (949) 595-7200	

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment
of _____ Certain Officers; Compensatory Arrangements of Certain Officers.
SIGNATURES

Table of Contents

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On October 22, 2007, Karen Uyesugi notified Endologix, Inc. (the Company) that she is resigning from her position as Vice President, Clinical and Regulatory Affairs and Quality Assurance of the Company effective as of November 16, 2007. Ms. Uyesugi is resigning to pursue other opportunities.

(e) In connection with Ms. Uyesugi's resignation, the Compensation Committee of the Board of Directors of the Company has approved an amendment to the Option Agreements between the Company and Ms. Uyesugi to provide that the outstanding options held by Ms. Uyesugi may be exercised at any time within twelve months after the effective date of her resignation.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENDOLOGIX, INC.

October 25, 2007

/s/ Robert J. Krist
Robert J. Krist
Chief Financial Officer